JP2016520615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520615A5 JP2016520615A5 JP2016517030A JP2016517030A JP2016520615A5 JP 2016520615 A5 JP2016520615 A5 JP 2016520615A5 JP 2016517030 A JP2016517030 A JP 2016517030A JP 2016517030 A JP2016517030 A JP 2016517030A JP 2016520615 A5 JP2016520615 A5 JP 2016520615A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- disease
- group
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829713P | 2013-05-31 | 2013-05-31 | |
| US61/829,713 | 2013-05-31 | ||
| PCT/US2014/040160 WO2014194166A1 (en) | 2013-05-31 | 2014-05-30 | Methods of using il-1 antagonists to treat alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076729A Division JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520615A JP2016520615A (ja) | 2016-07-14 |
| JP2016520615A5 true JP2016520615A5 (https=) | 2017-05-18 |
Family
ID=51023151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517030A Pending JP2016520615A (ja) | 2013-05-31 | 2014-05-30 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
| JP2018076729A Pending JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076729A Pending JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160120941A1 (https=) |
| EP (1) | EP3003356B1 (https=) |
| JP (2) | JP2016520615A (https=) |
| AU (1) | AU2014274044B2 (https=) |
| CA (1) | CA2911547A1 (https=) |
| WO (1) | WO2014194166A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016187339A1 (en) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOIDß |
| CN110177572A (zh) * | 2016-09-12 | 2019-08-27 | 史蒂文·霍夫曼 | 用于治疗痴呆的组合物 |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| WO2019152627A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN111956933B (zh) * | 2020-08-27 | 2022-05-03 | 北京理工大学 | 一种阿尔兹海默病神经反馈康复系统 |
| WO2022167916A1 (en) * | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
| WO2023132698A1 (ko) * | 2022-01-10 | 2023-07-13 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965421A (en) * | 1997-11-26 | 1999-10-12 | Human Genome Sciences, Inc. | Human IRAK-2 |
| US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US7629311B2 (en) * | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| AU2002320100A1 (en) * | 2001-06-15 | 2003-01-02 | Interleukin Genetics, Inc. | Methods for detecting and treating the early onset of aging-related conditions |
| US7790867B2 (en) * | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
| US20050129685A1 (en) * | 2003-09-18 | 2005-06-16 | Jingtai Cao | Use of IL-1 blockers to prevent corneal inflammation and neovascularization |
| US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP1750746A1 (en) * | 2004-06-04 | 2007-02-14 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| WO2006066089A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| DK1899378T3 (da) * | 2005-06-21 | 2010-02-01 | Xoma Technology Ltd | IL-1 beta-bindende antistoffer og fragmenter deraf |
| US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
| US20110159011A1 (en) * | 2008-08-28 | 2011-06-30 | Wyeth Llc | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| WO2011127933A1 (en) * | 2010-04-16 | 2011-10-20 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
| CN103221422B (zh) * | 2010-07-29 | 2017-03-29 | 十一生物治疗股份有限公司 | 嵌合il‑1受体i型激动剂和拮抗剂 |
| EP2686431B1 (en) * | 2011-03-14 | 2016-08-03 | Phlogo ApS | Antagonists of the interleukin- 1 receptor |
-
2014
- 2014-05-30 JP JP2016517030A patent/JP2016520615A/ja active Pending
- 2014-05-30 CA CA2911547A patent/CA2911547A1/en not_active Abandoned
- 2014-05-30 US US14/893,932 patent/US20160120941A1/en not_active Abandoned
- 2014-05-30 AU AU2014274044A patent/AU2014274044B2/en not_active Ceased
- 2014-05-30 WO PCT/US2014/040160 patent/WO2014194166A1/en not_active Ceased
- 2014-05-30 EP EP14733888.3A patent/EP3003356B1/en active Active
-
2018
- 2018-04-12 JP JP2018076729A patent/JP2018111723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520615A5 (https=) | ||
| Wes et al. | Targeting microglia for the treatment of Alzheimer's Disease | |
| Cao et al. | Postoperative cognitive deficits and neuroinflammation in the hippocampus triggered by surgical trauma are exacerbated in aged rats | |
| Okuma et al. | Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1–RAGE interaction | |
| Ryu et al. | Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer’s disease | |
| JP2011507891A5 (https=) | ||
| JP2017158561A5 (https=) | ||
| JP2017042172A5 (https=) | ||
| HRP20210559T1 (hr) | Pripravci i postupci inhibiranja masp-1 i/ili masp-2 i/ili masp-3 za liječenje raznih bolesti i poremećaja | |
| Ma et al. | Ribonuclease attenuates hepatic ischemia reperfusion induced cognitive impairment through the inhibition of inflammatory cytokines in aged mice | |
| Ahmed et al. | Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals—A randomized double-blind pre-clinical study | |
| JP2018511327A5 (https=) | ||
| Goel et al. | Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: protection by angiotensin converting enzyme inhibition | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2013533287A5 (https=) | ||
| JP2017537105A5 (https=) | ||
| JP2019519533A5 (https=) | ||
| JP2019518779A5 (https=) | ||
| EP3368032A1 (en) | Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease | |
| JP2018516944A5 (https=) | ||
| JP2018529661A5 (https=) | ||
| JP2018534259A5 (https=) | ||
| JP2017518316A5 (https=) | ||
| JP2018530574A5 (https=) | ||
| JP2014529606A5 (https=) |